Carboplatin hypersensitivity reaction in pediatric patients with low‐grade glioma

Abstract

Forty-two percent of children with LGG who received carboplatin regimens experienced Cb HSR. Most rechallenged children had recurrent Cb HSR despite Cb HSR-altering regimens. Cb HSR did not have an impact on progression-free survival.